168 related articles for article (PubMed ID: 30410117)
1. A rapamycin derivative, biolimus, preferentially activates autophagy in vascular smooth muscle cells.
Kim Y; Park JK; Seo JH; Ryu HS; Lim KS; Jeong MH; Kang DH; Kang SW
Sci Rep; 2018 Nov; 8(1):16551. PubMed ID: 30410117
[TBL] [Abstract][Full Text] [Related]
2. Two-dimensional fluorescence in-gel electrophoresis of coronary restenosis tissues in minipigs: increased adipocyte fatty acid binding protein induces reactive oxygen species-mediated growth and migration in smooth muscle cells.
Lu L; Wang YN; Sun WH; Liu ZH; Zhang Q; Pu LJ; Yang K; Wang LJ; Zhu ZB; Meng H; Yang P; Du R; Chen QJ; Wang LS; Yu H; Shen WF
Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):572-80. PubMed ID: 23372061
[TBL] [Abstract][Full Text] [Related]
3. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model.
Tada N; Virmani R; Grant G; Bartlett L; Black A; Clavijo C; Christians U; Betts R; Savage D; Su SH; Shulze J; Kar S
Circ Cardiovasc Interv; 2010 Apr; 3(2):174-83. PubMed ID: 20407114
[TBL] [Abstract][Full Text] [Related]
4. Enhanced sterol response element-binding protein in postintervention restenotic blood vessels plays an important role in vascular smooth muscle proliferation.
Zhou RH; Pesant S; Cohn HI; Eckhart AD
Life Sci; 2008 Jan; 82(3-4):174-81. PubMed ID: 18068195
[TBL] [Abstract][Full Text] [Related]
5. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
[TBL] [Abstract][Full Text] [Related]
6. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin-eluting stents in the arterial duct: experimental observations in the pig model.
Lee KJ; Hinek A; Chaturvedi RR; Almeida CL; Honjo O; Koren G; Benson LN
Circulation; 2009 Apr; 119(15):2078-85. PubMed ID: 19349326
[TBL] [Abstract][Full Text] [Related]
8. Activation of Peroxisome Proliferator-Activated Receptor-δ as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis.
Hytönen J; Leppänen O; Braesen JH; Schunck WH; Mueller D; Jung F; Mrowietz C; Jastroch M; von Bergwelt-Baildon M; Kappert K; Heuser A; Drenckhahn JD; Pieske B; Thierfelder L; Ylä-Herttuala S; Blaschke F
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1534-48. PubMed ID: 27283742
[TBL] [Abstract][Full Text] [Related]
9. Association of Serum HMGB2 Levels With In-Stent Restenosis: HMGB2 Promotes Neointimal Hyperplasia in Mice With Femoral Artery Injury and Proliferation and Migration of VSMCs.
He YH; Wang XQ; Zhang J; Liu ZH; Pan WQ; Shen Y; Zhu ZB; Wang LJ; Yan XX; Yang K; Zhang RY; Shen WF; Ding FH; Lu L
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):717-729. PubMed ID: 28183701
[TBL] [Abstract][Full Text] [Related]
10. Enhanced autophagy by everolimus contributes to the antirestenotic mechanisms in vascular smooth muscle cells.
Tang B; Dong X; Wei Z; Qiao H; Jiang H; Liu B; Sun X
J Vasc Res; 2014; 51(4):259-68. PubMed ID: 25196016
[TBL] [Abstract][Full Text] [Related]
11. Experimental efficacy of an everolimus eluting cobalt chromium stent.
Carter AJ; Brodeur A; Collingwood R; Ross S; Gibson L; Wang CA; Haller S; Coleman L; Virmani R
Catheter Cardiovasc Interv; 2006 Jul; 68(1):97-103. PubMed ID: 16755598
[TBL] [Abstract][Full Text] [Related]
12. Effect of alpha lipoic acid in a porcine in-stent restenosis model.
Lim SY; Bae EH; Jeong MH; Kim JH; Hong YJ; Sim DS; Kim YS; Park IK; Ahn Y; Song SJ; Cho DL; Kim KS; Kang JC
J Cardiol; 2009 Dec; 54(3):375-85. PubMed ID: 19944312
[TBL] [Abstract][Full Text] [Related]
13. Exogenous SERP1 attenuates restenosis by restoring GLP-1 receptor activity in diabetic rats following vascular injury.
Feng L; Wang J; Ma X
Biomed Pharmacother; 2018 Jul; 103():290-300. PubMed ID: 29656185
[TBL] [Abstract][Full Text] [Related]
14. Fas ligand and nitric oxide combination to control smooth muscle growth while sparing endothelium.
Kural MH; Wang J; Gui L; Yuan Y; Li G; Leiby KL; Quijano E; Tellides G; Saltzman WM; Niklason LE
Biomaterials; 2019 Aug; 212():28-38. PubMed ID: 31102854
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells.
Clever YP; Cremers B; Krauss B; Böhm M; Speck U; Laufs U; Scheller B
EuroIntervention; 2011 May; 7 Suppl K():K32-42. PubMed ID: 22027725
[TBL] [Abstract][Full Text] [Related]
16. Antirestenotic mechanisms of everolimus on human coronary artery smooth muscle cells: inhibition of human coronary artery smooth muscle cell proliferation, but not migration.
Lavigne MC; Grimsby JL; Eppihimer MJ
J Cardiovasc Pharmacol; 2012 Feb; 59(2):165-74. PubMed ID: 21983747
[TBL] [Abstract][Full Text] [Related]
17. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.
Wessely R; Blaich B; Belaiba RS; Merl S; Görlach A; Kastrati A; Schömig A
Thromb Haemost; 2007 Jun; 97(6):1003-12. PubMed ID: 17549304
[TBL] [Abstract][Full Text] [Related]
18. Naringenin inhibits angiotensin II-induced vascular smooth muscle cells proliferation and migration and decreases neointimal hyperplasia in balloon injured rat carotid arteries through suppressing oxidative stress.
Xu C; Chen J; Zhang J; Hu X; Zhou X; Lu Z; Jiang H
Biol Pharm Bull; 2013; 36(10):1549-55. PubMed ID: 23912743
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53.
Rosner D; McCarthy N; Bennett M
Cardiovasc Res; 2005 Jun; 66(3):601-10. PubMed ID: 15914125
[TBL] [Abstract][Full Text] [Related]
20. The Role of Tauroursodeoxycholic Acid on Dedifferentiation of Vascular Smooth Muscle Cells by Modulation of Endoplasmic Reticulum Stress and as an Oral Drug Inhibiting In-Stent Restenosis.
Luo H; Zhou C; Chi J; Pan S; Lin H; Gao F; Ni T; Meng L; Zhang J; Jiang C; Ji Z; Lv H; Guo H
Cardiovasc Drugs Ther; 2019 Feb; 33(1):25-33. PubMed ID: 30663009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
